
|Videos|October 31, 2017
Dr. Awan Discusses Combinations With Ibrutinib in CLL
Author(s)Farrukh Awan, MBBS
Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses combinations with ibrutinib (Imbruvica) in chronic lymphocytic leukemia.
Advertisement
Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses combinations with ibrutinib (Imbruvica) in chronic lymphocytic leukemia (CLL).
Combinations with ibrutinib have shown to be effective, but have not been proven to be superior to ibrutinib alone, says Awan.
The ALLIANCE trial compared ibrutinib to ibrutinib plus rituximab and chemoimmunotherapy, results of which could clarify the argument of monotherapy versus combination.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5


































